Zacks Investment Small Cap Research Issues Quarterly Update on E-QURE

Initiates Coverage on E-QURE with Buy Rating and Target Price of $2.50 per share

May 27, 2015, 11:23 ET from E-QURE, Corp.

DOVER, Delaware, May 27, 2015 /PRNewswire/ --

E-QURE, Corp. (OTCQB: EQUR), a Delaware corporation engaged in the development and commercialization of its Bio-electrical Signal Therapy device ("BST Device"), a new and novel electrotherapy for the noninvasive treatment of hard to heal chronic wounds, today announced that on May 19, 2015, Zacks Small Cap Research issued a quarterly update on E-CURE Corp found here. According to Zacks' research update, E-QURE Corp "…has a compelling story and (Zacks) believes valuation might increase as certain risks abate."

Included in the valuation and recommendation section of the report, analysts state "Our revenue estimate of $10 million in 2018 with an EPS of $0.09 is based on our assumption that about 500 units and 200,000 electrodes are placed in wound management clinics and hospitals worldwide. Due to what we view as significant advantages of the BST device provide over the existing devices in the market, we think our revenue estimates could prove conservative. Based on the current market price we feel the shares are undervalued. Using a Discounted Cash Flow (DCF) analysis, we derive the total equity value of approximately $50 million. We initiate coverage on EQUR with an Outperform rating with a target price of $3.50/share."

The Zacks report also discusses E-QURE's competitive landscape and opportunity, "We believe that there is a moderate potential for EQUR's BST device within this arena as EQUR has optimally priced their product significantly lower than that of competitors. Additionally, having a global presence in the advanced wound care management business and efforts to capitalize from high growth opportunities in this market would keep EQUR in business. If EQUR gets approval from the FDA via the PMA pathway, although more challenging, may lead to pay or coverage thereby paving way for commercializing their device in the US, after which there is wide scope to increase adoption in other regions of world."

The report was made public on May 20 2015, and is available on public sources, the Zacks site and the E-QURE site.

About E-QURE  

E-QURE Corp (OTCQB: EQUR) develops, manufactures and markets the E-QURE BST (Bioelectrical Signal Therapy) Device for the treatment and cure of chronic wounds such as; pressure ulcers; diabetics foot ulcers; venous stasis ulcers and; hard to heal ulcers. The E-QURE BST device had few regulatory approvals in different part of the world that are currently being renewed. The company is seeking FDA approval for the device to start marketing it in the US.

Safe Harbor Statement 

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements, when we discuss the potential of E-QURE BST device to treat wounds.  These forward-looking statements and their implications are based on the current expectations of the management of E-QURE only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of E-QURE to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, ADBI undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting E-QURE, reference is made to E-QURE reports filed from time to time with the Securities and Exchange Commission.

Investor Relations:
Howard Gostfrand
American Capital Ventures